EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
KNOWLEDGE BANK
-
Articles
Why Biopharma is switching to Single-Use Systems: Cost, Quality, and Flexibility
Singleuse biopharma systems have replaced traditional stainlesssteel systems in the biopharmaceutical industry because of a major industry transformation What factors lead the market toward this direction Major factors that drive the industry involve establishing savings from singleuse equipment in pharmaceutical applications
Antibody-Drug Conjugates (ADCs): Driving the Next Generation of Precision Oncology
An antibodydrug conjugate is a targeted cancer therapy that links a potent cytotoxic drug to a monoclonal antibody through a chemical linker so the antibody delivers the payload directly to tumour cells expressing a chosen antigen The design widens the therapeutic window it concentrates cytotoxic activity where the target is expressed and limits the systemic exposure that constrains conventional c...
Maximizing ROI: The Secret to Successful Pharma Magazine Advertising
Advertisement through pharma magazines has for a long time remained common in most marketing strategies for pharma industries Its been around and it provides the best chance to engage with pharma professional other industry players and even a wellinformed populace However more especially given that the modern world is a digital realm there are always issues pertaining to the effectiveness of such...
Drug Approval Strategies and Regulatory Pathways in the Pharmaceutical Industry
Getting a new medicine to patients is never just a scientific achievement Its also a regulatory one A molecule can be brilliant in the lab and still stall for years if the drug approval process isnt planned properly from day one Thats why across the pharmaceutical industry regulatory strategy has quietly become just as important as clinical data itself
Next-Gen Continuous Biomanufacturing: Redefining Efficiency and Quality Standards
Continuous biomanufacturing represents a paradigm shift in the production of biopharmaceuticals offering unparalleled efficiency flexibility and quality control compared to traditional batch processes
Using Mass Spectrometry as Quality Control in Medicinal Cannabis
Cannabis plants contain a wide variety of complex compounds including phytocannabinoids terpenoids and flavonoids found mainly in the inflorescences Major phytocannabinoids like CBD and THC have beneficial effects on human health
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Antibody-Drug Conjugates (ADCs): Driving the Next Generation of Precision Oncology
Lakshmi
Antibody-drug conjugates have moved from salvage therapy to the strategic centre of precision oncology. With more than twenty ADCs approved worldwide and hundreds in development, the decisive question...
-
2
Maximizing ROI: The Secret to Successful Pharma Magazine Advertising
Kate Williamson
Print media particularly magazines continue to offer a valuable way of reaching a well-inspected, informed audience mostly within the pharma sector. Ultimately, through identifying the audience, telli...
-
3
Drug Approval Strategies and Regulatory Pathways in the Pharmaceutical Industry
Kate Williamson
This article explores drug approval strategies and regulatory pathways across major pharmaceutical markets, with a focus on European medicines approvals. It breaks down the marketing authorisation pro...
-
4
Next-Gen Continuous Biomanufacturing: Redefining Efficiency and Quality Standards
Kate Williamson
Explore the transformative realm of next-gen continuous biomanufacturing, revolutionizing biopharmaceutical production with efficiency, quality control, and flexibility. Uncover key components, benefi...
-
5
Using Mass Spectrometry as Quality Control in Medicinal Cannabis
Dalia Goldhaber-Pasillas
Cannabis plants contain a wide variety of complex compounds including phytocannabinoids, terpenoids and flavonoids, found mainly in the inflorescences. Major phytocannabinoids like CBD and ∆9-THC have...
press releases Read more...
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
MacroGenics Inc a clinicalstage biopharmaceutical company focused on developing innovative antibodybased therapeutics for the treatment of cancer today announced that the first patient has been dosed in the Phase study of MGC a firstinclass antibodydrug conjugate
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
Legend Biotech Corporation a global leader in cell therapy today announced that the US Food and Drug Administration FDA has cleared the investigational new drug IND application for LB an investigational in vivo CART therapy designed to generate CDCD dualtargeting chimeric antigen receptor T
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
Eikon Therapeutics Inc a latestage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs today announced the submission of an Investigational New Drug IND application to the US Food and Drug Administration FDA to evaluate EIK for the t...
Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome
Orvida Pharma a clinicalstage biotechnology company developing first and bestinclass treatments for rare and severe genetic skin diseases today announced that the US Food and Drug Administration FDA has accepted KM ontivatrep the Companys lead oral investigational therapy for Olmsted syndrome
Events Read more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026Pharma Manufacturing & Automation Convention 2026
Novotel Hyderabad Airport, Ind...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWS Read more...
AtomVie Global Radiopharma Announces Strategic Partnership with Jubilant Radiopharma to Strengthen Logistics and Distribution in Clinical Trials
AtomVie Global Radiopharma a global contract developer and manufacturer CDMO for radiopharmaceuticals today announced a strategic partnership with Jubilant DraxImage Inc operating as Jubilant Radiopharma Jubilant Radiopharma to provide logistics approval and lastmile distribution services to support
Transcripta Bio Announces Research Collaboration to Advance Discovery of New ALS Treatments
Transcripta Bio an AIpowered drug discovery company focused on neurological and neuromuscular diseases today announced a research collaboration and licensing agreement with Mayo Clinic centered on amyotrophic lateral sclerosis ALS a fatal neurodegenerative disease with few effective treatments
Insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies
Insitro an AI company unlocking causal human biology to systematically generate highvalue therapeutics to treat grievous illness today announced a worldwide exclusive research collaboration agreement with AstraZeneca to discover novel targets and therapeutics in metabolic dysfunctionassociated steat...
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
Vir Biotechnology Inc announced a collaboration and license agreement with Gilead to discover and engineer three novel PROXTEN dualmasked Tcell engager TCE development candidates targeting selected solid tumorassociated antigens Gilead will have an exclusive license to develop and commercialize
Genezen and Galibra Neuroscience Partner to Advance Gene Therapy for SSADH Deficiency Toward First-in-Human Trial
Genezen a gene therapy contract development and manufacturing organization CDMO and Galibra Neuroscience a biotechnology company developing transformative therapies for rare neurological disorders today announced a manufacturing partnership to advance Galibras GAL program an AAVbased gene therapy fo...
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Zealand Pharma AS a biotechnology company transforming the future of metabolic health today announced a multitarget strategic collaboration with Generate Biomedicines Inc Under the collaboration the companies intend to design and develop multispecific protein therapeutics





